[go: up one dir, main page]

LT3442580T - Cholestazinių ir fibrozinių ligų gydymo būdai - Google Patents

Cholestazinių ir fibrozinių ligų gydymo būdai

Info

Publication number
LT3442580T
LT3442580T LTEP17710285.2T LT17710285T LT3442580T LT 3442580 T LT3442580 T LT 3442580T LT 17710285 T LT17710285 T LT 17710285T LT 3442580 T LT3442580 T LT 3442580T
Authority
LT
Lithuania
Prior art keywords
cholestatic
treatment
methods
fibrotic diseases
fibrotic
Prior art date
Application number
LTEP17710285.2T
Other languages
English (en)
Inventor
Raphaël Darteil
Robert Walczak
Carole Belanger
Emilie Negro
Pierre Daubersies
Philippe Delataille
Original Assignee
Genfit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfit filed Critical Genfit
Publication of LT3442580T publication Critical patent/LT3442580T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
LTEP17710285.2T 2016-04-11 2017-03-13 Cholestazinių ir fibrozinių ligų gydymo būdai LT3442580T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305425 2016-04-11
PCT/EP2017/055878 WO2017178172A1 (en) 2016-04-11 2017-03-13 Methods of treatment for cholestatic and fibrotic diseases

Publications (1)

Publication Number Publication Date
LT3442580T true LT3442580T (lt) 2020-12-28

Family

ID=55755536

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP17710285.2T LT3442580T (lt) 2016-04-11 2017-03-13 Cholestazinių ir fibrozinių ligų gydymo būdai

Country Status (24)

Country Link
US (7) US20170290812A1 (lt)
EP (3) EP3777855B1 (lt)
JP (1) JP6894923B2 (lt)
KR (1) KR102431257B1 (lt)
CN (1) CN109069648B (lt)
AU (1) AU2017249602B2 (lt)
CA (1) CA3019399A1 (lt)
DK (2) DK3777855T3 (lt)
EA (2) EA202191466A1 (lt)
ES (3) ES2839453T3 (lt)
HR (1) HRP20201954T1 (lt)
HU (2) HUE052886T2 (lt)
IL (1) IL262052B (lt)
LT (1) LT3442580T (lt)
MD (1) MD3442580T2 (lt)
MX (1) MX384261B (lt)
MY (1) MY195437A (lt)
PH (1) PH12018502142B1 (lt)
PL (1) PL3442580T3 (lt)
PT (2) PT3442580T (lt)
SG (2) SG10202004425XA (lt)
SI (1) SI3442580T1 (lt)
WO (1) WO2017178172A1 (lt)
ZA (1) ZA201807389B (lt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019513762A (ja) * 2016-04-11 2019-05-30 ジェンフィＧｅｎｆｉｔ 胆汁うっ滞及び線維症の処置方法
MX384261B (es) 2016-04-11 2025-03-14 Genfit Metodos de tratamiento para enfermedades colestasicas y fibroticas.
IL268751B (en) * 2017-03-13 2022-08-01 Genfit Pharmaceutical preparations for combined treatment
AU2018238577B2 (en) * 2017-03-21 2023-02-02 Novalead Pharma Inc. Therapeutic agent for phosphodiesterase inhibition and its related disorders
JP7365054B2 (ja) * 2017-11-17 2023-10-19 ケスター，ヒューバート リンパ管平滑筋腫症及びその他の疾患に使用するための［２－［（５－ニトロ－１，３－チアゾール－２－イル）カルバモイル］フェニル］エタノエート
EP3639822A1 (en) * 2018-10-15 2020-04-22 Universität Regensburg Compound for use in the treatment of a disease characterized by dysregulated mucus production and/or secretion
MA55592A (fr) 2019-04-10 2022-02-16 Genfit Polythérapie comprenant des composés de formule (i) et des agonistes du récepteur glp-1
BR112021020496A2 (pt) * 2019-04-12 2021-12-07 Genfit Nitazoxanida e tiazolidas para uso no tratamento de doenças associadas ao estresse oxidativo
CN110205302B (zh) * 2019-06-24 2021-03-23 扬州大学 一株分泌抗麦考酚酸单克隆抗体的细胞株、其单克隆抗体及其应用
CN110478357A (zh) * 2019-07-23 2019-11-22 哈尔滨医科大学 硝唑尼特及其体内代谢物在抗肥胖、降血脂、抗脂肪肝及抗动脉粥样硬化中的应用
CN110368498A (zh) * 2019-08-26 2019-10-25 瑞希(重庆)生物科技有限公司 一种促进伤口愈合的制剂及其制备方法
CN114630660A (zh) 2019-10-28 2022-06-14 基恩菲特公司 具有抗氧化特性的联合疗法
CN113398125B (zh) * 2020-03-16 2024-05-03 绍兴君科臻元医药科技有限公司 替唑尼特药物组合物及其医药用途
CA3196479A1 (en) * 2020-11-17 2022-05-27 Philippe Delataille Methods of treatment of liver failure
CN116507343A (zh) * 2020-11-17 2023-07-28 基恩菲特公司 治疗肝衰竭的方法
WO2022218239A1 (zh) * 2021-04-12 2022-10-20 杜心赟 新型噻唑类化合物及其制备方法和用途
CN116077502B (zh) * 2021-11-05 2025-12-23 广州医科大学附属妇女儿童医疗中心 叶酸在预防、诊断和治疗胆道闭锁中的应用
AU2023355753A1 (en) * 2022-10-04 2025-04-03 Genfit Nitazoxanide for the treatment of hepatic impairment
CN116911513B (zh) * 2023-02-07 2024-07-26 中国药科大学 硝唑尼特及其体内代谢物替唑尼特在制备抗心衰药物中的应用
WO2025063816A1 (ko) * 2023-09-21 2025-03-27 오토텔릭바이오 주식회사 티아졸 유도체 화합물을 포함하는 자궁 섬유화증 치료용 조성물
CN117838690B (zh) * 2023-10-09 2024-09-13 中国药科大学 一种治疗以ampk激活为治疗靶点的疾病的复方药物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
US6114365A (en) 1999-08-12 2000-09-05 Pharmacia & Upjohn S.P.A. Arylmethyl-carbonylamino-thiazole derivatives, process for their preparation, and their use as antitumor agents
CA2436739A1 (en) 2000-12-26 2002-07-04 Takeda Chemical Industries, Ltd. Combination agent
AU2004272599A1 (en) 2003-09-06 2005-03-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
EP2540296A1 (en) 2005-06-03 2013-01-02 Xenon Pharmaceuticals Inc. Arminothiazole derivatives as human stearoyl-coa desaturase inhibitors
US20100056505A1 (en) 2005-11-21 2010-03-04 Biogen Idec Ma Inc. Substituted Pyrazalones
AU2007204963B2 (en) * 2006-01-09 2012-09-27 Romark Laboratories, L.C. Viral hepatitis treatment
WO2007087427A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
GB0619500D0 (en) 2006-10-03 2006-11-08 Univ Keele Treatment of fibrosis
CN101835765B (zh) 2007-08-03 2013-05-29 罗马克实验室有限公司 烷基磺酰基取代的噻唑化物类化合物
WO2009023509A2 (en) * 2007-08-09 2009-02-19 Vertex Pharmaceuticals Incorporated Therapeutic combinations useful in treating cftr related diseases
KR101045572B1 (ko) 2007-08-14 2011-07-01 주식회사 엘지화학 Ｃｌｏｓｔｒｉｄｉｕｍ ｐｒｏｐｉｏｎｉｃｕｍ 유래의프로피오닐―ＣｏＡ 트랜스퍼라아제 변이체 및 상기변이체를 이용한 락테이트 중합체 또는 락테이트공중합체의 제조방법
WO2009039246A2 (en) 2007-09-18 2009-03-26 Stanford University Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection
US9149463B2 (en) * 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US20100016262A1 (en) 2007-10-18 2010-01-21 Yale University Compositions and methods for reducing hepatotoxicity associated with drug administration and treating non-alcoholic fatty liver disease, non-alcoholic steatohepatitis and associated cirrhosis
EP2408449A4 (en) * 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
AP3074A (en) 2009-05-12 2014-12-31 Romark Lab Lc Haloalkyl heteroaryl benzamide compounds
PT2445349T (pt) 2009-06-26 2022-05-16 Romark Laboratories Lc Compostos e métodos para tratamento da gripe
US8816074B2 (en) 2009-11-16 2014-08-26 University of Georgia Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
AU2010319999B2 (en) 2009-11-16 2014-01-16 University Of Georgia Research Foundation, Inc. 2'-Fluoro-6'-methylene carbocyclic nucleosides and methods of treating viral infections
WO2011140296A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles as inhibitors of fatty acid synthase
CA2798330A1 (en) 2010-05-05 2011-11-10 Infinity Pharmaceuticals, Inc. Tetrazolones as inhibitors of fatty acid synthase
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
WO2012027710A2 (en) 2010-08-27 2012-03-01 Calcimedica Inc. Compounds that modulate intracellular calcium
CN103269593A (zh) 2010-11-01 2013-08-28 罗马克实验室有限公司 烷基亚磺酰基取代的噻唑化物化合物
CN103635196B (zh) 2011-03-02 2019-05-07 J·深塔格 用于单独治疗肝脂肪变性或治疗伴有丙型肝炎病毒感染的肝脂肪变性的组合物、治疗方法和诊断方法
JP6138764B2 (ja) 2011-05-16 2017-05-31 ロマーク ラボラトリーズ エル．シー． ウイルス性疾患、ガンおよび細胞内感染により引き起こされる疾患の予防および処置のためのチアゾリド化合物の使用
WO2013059677A1 (en) 2011-10-19 2013-04-25 Calcimedica, Inc. Compounds that modulate intracellular calcium
AU2013202269A1 (en) * 2011-10-26 2013-05-16 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
WO2013082469A2 (en) 2011-12-02 2013-06-06 University Of Vermont And State Agricultural College Methods and compositions for treating infections
WO2014036528A2 (en) 2012-08-31 2014-03-06 Ixchel Pharma, Llc Agents useful for treating obesity, diabetes and related disorders
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
US9974767B2 (en) 2014-07-14 2018-05-22 University Of Washington Statins in the treatment of muscular dystrophies and myopathies
US10100023B2 (en) 2014-11-11 2018-10-16 Romark Laboratories, L.C. Compositions and methods of treatment with prodrugs of tizoxanide, an analogue or salt thereof
WO2016210247A1 (en) 2015-06-24 2016-12-29 Duke University New methods of use for an anti-diarrhea agent
MX384261B (es) 2016-04-11 2025-03-14 Genfit Metodos de tratamiento para enfermedades colestasicas y fibroticas.
JP2019513762A (ja) 2016-04-11 2019-05-30 ジェンフィＧｅｎｆｉｔ 胆汁うっ滞及び線維症の処置方法
CN109152760B (zh) 2016-04-11 2022-09-23 基恩菲特公司 胆汁淤积性和纤维化疾病的治疗方法

Also Published As

Publication number Publication date
ZA201807389B (en) 2020-01-29
US11103484B2 (en) 2021-08-31
EP3777854B1 (en) 2022-07-20
DK3442580T3 (da) 2020-12-21
JP6894923B2 (ja) 2021-06-30
ES2839453T3 (es) 2021-07-05
US20170290812A1 (en) 2017-10-12
US10117856B2 (en) 2018-11-06
SG10202004425XA (en) 2020-06-29
DK3777855T3 (da) 2023-01-09
EP3442580B1 (en) 2020-09-23
MX384261B (es) 2025-03-14
AU2017249602B2 (en) 2022-06-16
US10117855B2 (en) 2018-11-06
MX2018012287A (es) 2019-02-07
NZ746668A (en) 2024-12-20
EP3777854A1 (en) 2021-02-17
PH12018502142A1 (en) 2019-07-29
AU2017249602A1 (en) 2018-10-18
US20200316031A1 (en) 2020-10-08
HUE052886T2 (hu) 2021-05-28
IL262052A (en) 2018-11-29
EP3442580A1 (en) 2019-02-20
PT3777855T (pt) 2023-01-10
PH12018502142B1 (en) 2023-08-11
HRP20201954T1 (hr) 2021-02-05
JP2019513761A (ja) 2019-05-30
US10130612B2 (en) 2018-11-20
SG11201808402RA (en) 2018-10-30
HUE060671T2 (hu) 2023-04-28
EP3777855A1 (en) 2021-02-17
EP3777855B1 (en) 2022-10-19
US10130613B2 (en) 2018-11-20
EA202191466A1 (ru) 2021-12-31
BR112018069684A2 (pt) 2019-01-29
IL262052B (en) 2021-12-01
KR102431257B1 (ko) 2022-08-10
KR20180129934A (ko) 2018-12-05
SI3442580T1 (sl) 2021-01-29
ES2935185T3 (es) 2023-03-02
US20190000813A1 (en) 2019-01-03
CA3019399A1 (en) 2017-10-19
CN109069648A (zh) 2018-12-21
US20180085354A1 (en) 2018-03-29
CN109069648B (zh) 2022-01-14
US20180092886A1 (en) 2018-04-05
PT3442580T (pt) 2020-12-23
WO2017178172A1 (en) 2017-10-19
US20180092884A1 (en) 2018-04-05
US20180092885A1 (en) 2018-04-05
ES2928408T3 (es) 2022-11-17
PL3442580T3 (pl) 2021-04-06
MY195437A (en) 2023-01-20
EA201892298A1 (ru) 2019-04-30
MD3442580T2 (ro) 2021-04-30

Similar Documents

Publication Publication Date Title
ZA201807389B (en) Methods of treatment for cholestatic and fibrotic diseases
ZA201807084B (en) Methods of treatment of cholestatic diseases
ZA202006746B (en) Methods of treatment
IL253244A0 (en) Methods for treating retinal diseases
ZA201807390B (en) Methods of treatment for cholestatic and fibrotic diseases
HUS2500033I1 (hu) Intrahepatikus kolesztázisos betegségek kezelése
ZA201702214B (en) Methods of using interleukin-10 for treating diseases and disorders
IL274541A (en) A method for treating diseases of the digestive tract using Tradifitant
ZA201705877B (en) Method of treating diseases
ZA201808360B (en) Treatment of intrahepatic cholestatic diseases
GB201416832D0 (en) Methods of treatment
IL253847A0 (en) Methods of treating diseases
SG11202005850VA (en) Methods of treatment of hypertrigl yceridemia
GB201602802D0 (en) Method of treatment
EP3151824A4 (en) Methods of treating neurodevelopmental diseases and disorders
HK40001765A (en) Methods of treatment for cholestatic and fibrotic diseases
GB201500555D0 (en) Method and device for the treatment of diseases
EP3193935A4 (en) Treatment of fibrotic diseases
GB201512139D0 (en) Methods of treatment
GB201801249D0 (en) Methods of treatment
GB201621398D0 (en) Treatment of emt-associated disease
GB201418640D0 (en) Agents and methods for treatment of cancer
AU2014902173A0 (en) Methods of treating neurodevelopmental diseases and disorders
GB201414023D0 (en) Treatment of autoimmune diseases
GB201421511D0 (en) Methods of screening and treatment